Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Toni Wheeler who wrote (2738)	11/5/1999 10:40:00 AM
From: Toni Wheeler	Respond to of 2836

CEL-SCI Corporation Hires New Senior Director of Quality Assurance <<<VIENNA, Va., Nov. 5 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: HIV; Berlin Stock Exchange:LSR) announces that it has hired William B. Jones to fill the newly created position of Senior Director of Quality Assurance. Mr. Jones has held quality assurance and quality control management positions in the field of biotechnology for over 20 years. Geert Kersten, Chief Executive Officer of CEL-SCI says, "Mr. Jones' experience in validation and quality assurance of biologicals at several emerging biotech companies (e.g. Biogen and Systemix) will hopefully allow us to move our Multikine(TM) cancer product quickly from the current phase II studies into a final clinical trial that will support approval to market the drug. This is a very critical time for the Company and we are happy that Mr. Jones has decided to join our team." CEL-SCI Corporation is a biopharmaceutical company whose mission is to use the immune system to combat disease. Its leading product is an immune boosting product called Multikine, which is currently in 6 clinical trials against head & neck cancer and prostate cancer. "CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at cel-sci.com on the Internet." When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.>>> ------------------------------------------------------------------------ SOURCE: ÿCEL-SCI Corporation CONTACT: ÿMedia contact: Geert Kersten, Chief Executive Officer of CEL-SCI Corporation, 703-506-9460, or for Investor relations: Daryll Strahl, 970-377-2216, for CEL-SCI Corporation